Ikena Oncology Inc (IKNA)
$1.7
+0.02
(+1.19%)▲
Performance
- $1.67$1.73$1.70
1.56%
Downside
Day's Volatility :3.27%
Upside
1.73%
- $1.02$5.95$1.70
40.0%
Downside
52 Weeks Volatility :82.86%
Upside
71.43%
Returns
| Period | Ikena Oncology Inc | Sector (Health Care) | Index (Russel 2000) |
|---|---|---|---|
3 Months | 29.23% | 6.5% | 0.0% |
6 Months | 25.37% | 7.1% | 0.0% |
1 Year | -72.09% | 9.8% | 0.0% |
3 Years | -85.38% | 14.2% | -20.2% |
Highlights
Market Capitalization | 81.1M |
Book Value | $3.22 |
Earnings Per Share (EPS) | -1.57 |
Wall Street Target Price | 4.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -1963.76% |
Return On Assets TTM | -29.04% |
Return On Equity TTM | -48.28% |
Revenue TTM | 3.8M |
Revenue Per Share TTM | 0.09 |
Quarterly Revenue Growth YOY | -87.9% |
Gross Profit TTM | -48.7M |
EBITDA | -74.5M |
Diluted Eps TTM | -1.57 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.26 |
EPS Estimate Next Year | -1.05 |
EPS Estimate Current Quarter | -0.41 |
EPS Estimate Next Quarter | -0.39 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 135.29%
Technicals Summary
Sell
Neutral
Buy
Ikena Oncology Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Ikena Oncology Inc | 2.44% | 25.37% | -72.09% | -85.38% | -94.75% |
 Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
 Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
 Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
 Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Ikena Oncology Inc | 5.29 | NA | NA | -1.26 | -0.48 | -0.29 | NA | 3.22 |
Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Ikena Oncology Inc | Buy | $81.1M | -94.75% | 5.29 | 0.0% |
Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Ikena Oncology Inc
Decreasing Revenue
Revenue is down for the last 6 quarters, 6.40M → 659.0K (in $), with an average decrease of 33.0% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, -19.48M → -16.14M (in $), with an average increase of 20.7% per quarter
Vs NVO
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 133.7%
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 271.9%
Institutional Holdings
Bvf Inc
9.88%Fidelity Management and Research Company
8.67%Blue Owl Capital Holdings LP
8.06%Orbimed Advisors, LLC
7.33%Omega Fund Management LLC
4.66%BlackRock Inc
3.79%
Company Information
ikena oncology (formerly kyn therapeutics) is a clinical-stage biotechnology company that discovers and develops patient-directed, biomarker-driven therapies for cancer patients, by understanding what drives their disease. we are advancing multiple development and discovery programs: an ep4 receptor antagonist; an ahr antagonist; a kynurenine-degrading enzyme; a discovery-stage program targeting the hippo signaling pathway; and a discovery-stage program against an undisclosed target.. in addition to raising capital from top tier investors orbimed advisors and atlas venture, we have entered into a global strategic collaboration with celgene on the ahr antagonist and kynase programs. “at ikena, we begin with the end in mind. we focus on subgroups of patients based on their biomarker profiles who will most benefit from our immunotherapy and tumor cell-targeted drug candidates, ensuring that we can bring the right drug to the right patient battling cancer.” mark manfredi, chief executi
Organization | Ikena Oncology Inc |
Employees | 34 |
CEO | Dr. Mark Manfredi Ph.D. |
Industry | Services |
Discover More
Iheartmedia
$1.70
+1.19%
Gigacloud Technology Inc
$1.70
+1.19%
Qurate Retail Inc
$1.70
+1.19%
Madison Square Garden Entertainment Corp
$1.70
+1.19%
Xpel Inc
$1.70
+1.19%
Telecom Argentina S.a.
$1.70
+1.19%
Barrett Business Services Inc
$1.70
+1.19%
Stitch Fix, Inc. (class A Shares)
$1.70
+1.19%
Jack In The Box Inc.
$1.70
+1.19%